Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir.

Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822. © Crown copyright 2021.

Citation

Ditte Marie Kirkegaard-Klitbo, Magda Teresa Thomsen, Marco Gelpi, Flemming Bendtsen, Susanne Dam Nielsen, Thomas Benfield. Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Aug 02;73(3):e811-e814

Mesh Tags

Substances

PMID: 33493297

search → result